Sfoglia per AUTORE
NERI A
Collezione AO Cuneo

  

Items : 9

Efficacy of front-line ibrutinib versus fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: A retrospective multicenter "Real-World" study. in American journal of hematology / Am J Hematol. 2023 Feb;98(2):E24-E27. doi: 10.1002/ajh.26779. Epub 2022 Nov 25.

2023
AO Cuneo
AOU Città della Salute di Torino
AOU Alessandria
AOU Novara

Levi S; Trentin L; Foà R; Cuneo A; Herishanu Y; Gentile M; Perry C; Gattei V; Gaidano G; Rossi D; Neri A; Olivieri J; Bomben R; Zucchetto A; Visentin A; Loseto G; Pietrasanta D; Chiarenza A; Braester A; Murru R; Aviv A; Varettoni M; Coscia M; Tadmor T; Shvidel L; Sportoletti P; Laurenti L; Reda G; Ruchlemer R; et alii...

High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 - VERITAS study. in Haematologica / Haematologica. 2023 Aug 1;108(8):2091-2100. doi: 10.3324/haematol.2022.282116.

2023
AOU Alessandria
AO Cuneo
AOU Città della Salute di Torino
AO Ordine Mauriziano
ASL Cuneo 1
AOU Novara

Fazi P; Vignetti M; Piciocchi A; Cuneo A; Foà R; Guarini A; Nanni M; Neri A; De Propris MS; De Novi LA; Visentin A; Vitale C; Albano F; Molinari MC; Pietrasanta D; Mattiello V; Liberati AM; Giordano A; Gottardi D; Patrizi VB; Galieni P; Musuraca G; Deodato M; Arcari A; Tani M; Levato L; Marchetti M; Massaia M; Rigolin GM; et alii...

Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study. in American journal of hematology / Am J Hematol. 2021 May 1;96(5):E168-E171. doi: 10.1002/ajh.26127. Epub 2021 Feb 24.

2021
AO Cuneo
AOU Città della Salute di Torino
AOU Alessandria
AOU Novara

Gentile M; Gattei V; Foà R; Ferrarini M; Polliack A; Gaidano G; Trentin L; Cuneo A; Fronza G; Cutrona G; Rossi D; Di Raimondo F; Neri A; Bomben R; Biagi A; Del Giudice I; Angeletti I; Galimberti S; Rago A; Caracciolo D; Cassin R; D'Arrigo G; Mendicino F; Botta C; Martino EA; Vigna E; Zucchetto A; Rossi FM; Scortechini I; et alii...

Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study. in Cancers / Cancers (Basel). 2021 Dec 31;14(1):207. doi: 10.3390/cancers14010207.

2021
AO Cuneo
ASL Cuneo 1
AOU Città della Salute di Torino
AO Ordine Mauriziano
AOU Alessandria
AOU Novara

Piciocchi A; Cuneo A; Foà R; Fazi P; Neri A; Guarini A; Rigolin GM; Nanni M; De Propris MS; Della Starza I; Raponi S; Del Giudice I; Murru R; Ruocco V; Ibatici A; Varettoni M; Laurenti L; Chiarenza A; Zinzani PL; Gentile M; Molinari A; Gozzetti A; Tani M; Musuraca G; Gottardi D; Re F; Orsucci L; Liberati AM; Ilariucci F; et alii...

TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases. in American journal of hematology / Am J Hematol. 2021 Aug 1;96(8):E306-E310. doi: 10.1002/ajh.26235. Epub 2021 May 25.

2021
AO Cuneo
AOU Città della Salute di Torino
AOU Alessandria
AOU Novara

Gentile M; Gattei V; Ferrarini M; Foà R; Polliack A; Trentin L; Cuneo A; Gaidano G; Di Raimondo F; Rossi D; Olivieri J; Jaksic O; Bomben R; Neri A; Fronza G; Rago A; Angeletti I; Cutrona G; Del Giudice I; Biagi A; Galimberti S; D'Arrigo G; Al-Janazreh H; Martino EA; Vigna E; Tripepi G; Zucchetto A; Rossi FM; Recchia AG; et alii...

Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials. in American journal of hematology / Am J Hematol. 2021 Aug 1;96(8):E269-E272. doi: 10.1002/ajh.26201. Epub 2021 May 3.

2021
AO Cuneo
AOU Città della Salute di Torino
AOU Alessandria
AOU Novara

D Arrigo G; Murru R; Gentile M; Gattei V; Polliack A; Trentin L; Gaidano G; Di Raimondo F; Cuneo A; Cutrona G; Rossi D; Menichini P; Olivieri J; Fronza G; Monti P; Del Giudice I; Bomben R; Neri A; Angeletti I; Biagi A; Rago A; Martino EA; Cassin R; Galimberti S; Foà R; Ferrarini M; Scortechini I; Rossi FM; Zucchetto A; et alii...

Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases. in European journal of haematology / Eur J Haematol. 2021 Apr;106(4):493-499. doi: 10.1111/ejh.13573. Epub 2021 Jan 28.

2021
AO Cuneo
AOU Città della Salute di Torino
AOU Alessandria
AOU Novara

Gentile M; Gattei V; Ferrarini M; Foà R; Trentin L; Polliack A; Gaidano G; Cuneo A; Di Raimondo F; Rossi D; Jaksic O; Monti P; Cutrona G; Bomben R; Neri A; Fronza G; Menichini P; Biagi A; Del Giudice I; Angeletti I; Rago A; Galimberti S; Cassin R; D'Arrigo G; Mendicino F; Martino EA; Vigna E; Al-Janazreh H; Zucchetto A; et alii...

Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib-rituximab. in Blood cancer journal / Blood Cancer J. 2020 Sep 16;10(9):92. doi: 10.1038/s41408-020-00358-3.

2020
AOU Città della Salute di Torino
AO Cuneo
AOU Alessandria
AOU Novara

Gattei V; Morabito F; Ferrarini M; Gaidano G; Cuneo A; Foà R; Trentin L; Fronza G; Cutrona G; Di Raimondo F; Angeletti I; Bomben R; Neri A; D'Arrigo G; Tripepi G; Vitale C; Al-Janazreh H; Rossi FM; Zucchetto A; Scortechini I; Consoli U; Loseto G; Pietrasanta D; Bossio S; Moia R; Recchia AG; Lucia E; Mendicino F; Vigna E; et alii...

High rate of MRD-responses in young and fit patients with IGHV mutated chronic lymphocytic leukemia treated with front-line fludarabine, cyclophosphamide, and intensified dose of ofatumumab (FCO2). in Haematologica / Haematologica. 2020 Nov 1;105(11):2671-2674. doi: 10.3324/haematol.2019.235705.

2020
AOU Città della Salute di Torino
AO Cuneo
AOU Alessandria

Foà R; Guarini AR; Raponi S; De Propris MS; Della Starza I; Del Giudice I; Albano F; Cuneo A; Neri A; Piciocchi A; Vignetti M; Nanni M; Musolino C; Battistini R; Del Poeta G; Pietrasanta D; Gozzetti A; Liberati AM; Reda G; Tedeschi A; Re F; Soddu S; Mauro FR; Angelucci E; Zaja F; Coscia M; Ilariucci F; Molica S;